12 Feb Parkinson’s Disease-specific imaging: Enhancing precision in CNS clinical trials
The unmet need of Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disease of the central nervous system (CNS). The condition causes neurons in parts of the brain to become weak, damaged, and die, leading to symptoms of muscle stiffness, resting tremors, impaired balance, and problems with movement and expression. In addition to the obvious physical symptoms, people suffering from Parkinson’s disease often face mental and emotional health problems, difficulty swallowing and chewing, changes to their speech, skin, and sleep, as well as pain and fatigue, muscle cramps, and a whole range of potential cognitive and psychiatric issues. According to the World Health Organization, Parkinson’s disease is the world’s fastest growing neurological disorder, with prevalence having doubled in the last 25 years, accounting for almost 8.5 million cases globally.
Current treatment options focus on symptom management, including dopaminergic therapies and enzyme inhibitors, with no cure and no currently available treatments to stop disease progression. Parkinson’s disease, therefore, remains a significant research priority, with the focus currently placed on finding treatments that can effectively slow disease progression, while continuing to enhance existing symptomatic treatments. Research in this area is complex, given the heterogeneity of symptoms, gradual neurodegeneration, and subtle early disease changes, the combination of which makes clinical trial imaging particularly challenging. This article will consider the current landscape of PD-specific imaging modalities and their applications, as well as highlighting the role of an experienced imaging clinical research organization (CRO) in CNS clinical trials management.
Parkinson’s-specific imaging modalities
Due to the nature of the disease, Parkinson’s disease can be extremely difficult to image during clinical trials, as there are still parts of the underlying pathophysiology that we have yet to understand. Neurodegenerative changes occur gradually, and the symptoms are highly heterogeneous, often going masked for years prior to a formal diagnosis. Structural brain changes, particularly in early stages of PD, are subtle and do not always correlate with clinical presentation. This limits the sensitivity of conventional imaging approaches, which were traditionally used to rule out the diagnosis of other conditions, rather than formally diagnosing the disease.
Given the heterogeneous symptomatology and the absence of reliable and objective early-stage biomarkers, a one-size-fits-all imaging strategy is unlikely to be sufficient. Differences in the rate of disease stage, dominant motor vs non-motor disease characteristics, disease progression, and patient specific history highlight the need for a more personalized imaging and management strategy, combining structural, functional, and molecular imaging techniques to de-risk the clinical trials and enhance success in bringing therapies to the market.
Despite the challenges, advanced imaging techniques can provide useful markers in detecting early changes and tracking progression in PD. Neuroimaging modalities used in PD clinical research include structural-MRI, diffusion-MRI, neuro melanin sensitive MRI (NM-MT), MR spectroscopy (MRS), susceptibility-weighted imaging (SWI), functional MRI (fMRI), positron emission tomography (PET) with tracers targeting different mechanisms (i.e. glucose and α-synuclein pathology), and dopamine single photon emission computed tomography (SPECT), as well as combinations of these approaches.
An integrative multimodal imaging approach can prove superior to a single modality imaging method. When imaging strategies are designed in careful consideration of complex disease heterogeneity and diverse patient characteristics, and aligned with clinical trial objectives, successful multimodal imaging can improve patient stratification, support biomarker development, and ultimately result in the development of more effective, individualized treatments.
Given the complexities of PD clinical trial imaging, however, conducting Parkinson’s disease research requires the knowledge and CNS clinical trials infrastructure of an experienced imaging CRO.
The role of an imaging CRO
The value of a Parkinson’s-specific imaging pipeline in the context of complex multimodal clinical trial imaging is significant. Utilizing an end-to-end, structured framework to plan, acquire, process, and analyze global imaging data across multiple imaging modalities and heterogeneous populations supports rigorous quality control, regulatory alignment, and clinical trial integrity.
With vast experience delivering high-quality clinical trial imaging data to over 750+ CNS clinical trials, including 140+ Parkinson’s specific research studies, Perceptive Imaging is a preferred CNS clinical trial imaging partner for successful PD research, with a comprehensive AI-driven workflow that integrates multimodal imaging data across all global sites.
Why sponsors choose Perceptive:
- A history of leadership in CNS radiotracer development
- Established visual read paradigms
- Parkinson’s-specific imaging quantitative analysis
- Advanced neuroimaging techniques
- Scientific depth across CNS drug development
- Strong imaging core lab presence in APAC
Perceptive brings proprietary, enhanced, and operationalized analysis pipelines based on the Parkinson’s Progression Markers Initiative (PPMI), including both PET and MR imaging workflows. These tools are optimized for disease progression modeling and understanding therapeutic response and have been validated across multicenter studies.
Reach out today and one of our solution experts will be in touch to learn about your upcoming CNS clinical trials.
Resources
Nature. Parkinson disease therapy: current strategies and future research priorities. https://www.nature.com/articles/s41582-024-01034-x
World Health Organization. Parkinson disease. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease
Frontiers Neurology. Neuroimaging in Parkinson’s disease and Parkinsonism. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1153682/full
—
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and providers are not warranted or endorsed.
Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on February 12, 2026 by Marie Benz MD FAAD